The EuroNeurotrophin proposal has been evaluated positively and will therefore receive funding from the Horizon 2020 programme under grant agreement No 765704.
The project will start on the 1st January 2018 and run for 48 months. During this time, 14 Early Stage Researchers (ESRs) will be employed to address the major limitations of neurotrophins by developing novel small molecule, neurotrophin mimetics with favourable profiles of stability, tissue penetration and targeted biological
This approach requires highly skilled researchers that have a deep understanding of neurotrophins and their function, comprehend all steps of drug discovery and development for ND, and possess the necessary skills to translate results into novel new therapies by linking academia and industry. Recruitment for the open PhD positions will start early in the year 2018.